Evenity (Romosozumab) Patient Assistance for Low-Income Patients

Why Evenity Is Expensive and Why Assistance Matters

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation [1]. The drug received FDA approval in April 2019 for treatment of osteoporosis in postmenopausal women at high risk for fracture. Unlike bisphosphonates (which slow bone loss), romosozumab actively builds new bone while simultaneously reducing resorption. That dual mechanism makes it one of only a few true anabolic osteoporosis therapies on the market.

The price reflects that clinical position. At roughly $1,825 per injection and a 12-dose course, the total therapy cost approaches $21,900 before insurance. For patients on fixed incomes or those caught in insurance coverage gaps, this figure is prohibitive. A 2023 analysis in the Journal of Bone and Mineral Research found that high out-of-pocket costs were the single strongest predictor of osteoporosis treatment discontinuation, with abandonment rates exceeding 40% when monthly costs topped $100 [2]. Assistance programs exist precisely because medication adherence falls apart when cost barriers go unaddressed.

The good news: multiple overlapping programs can reduce or eliminate this cost. The strategy depends on your insurance status.

Amgen Assist: The Manufacturer's Free Drug Program

Amgen operates a patient assistance program called Amgen Assist that provides Evenity at no cost to eligible patients. This is the single most impactful resource for uninsured or underinsured individuals.

Eligibility criteria include household income at or below 300% of the Federal Poverty Level (FPL). For a single individual in 2026, that threshold is approximately $46,800 annually. Applicants must be U.S. residents, must not have coverage through a government insurance program that already covers the drug, and must have a valid prescription from a licensed provider. Patients enrolled in Medicare Part D who hit the coverage gap may also qualify under certain conditions.

The application requires proof of income (tax returns or pay stubs), a signed prescription, and a completed enrollment form from the prescribing physician's office. Processing typically takes 2 to 4 weeks. Once approved, the medication ships directly to the physician's office or an approved infusion center at zero cost to the patient.

One limitation worth knowing: Amgen Assist covers the drug itself but does not cover administration fees. If your provider charges a separate injection fee, that cost remains your responsibility. Ask the office staff whether they bill an administration charge and whether that charge can be waived or reduced for financial hardship cases.

The Evenity Copay Card for Commercially Insured Patients

Patients with commercial (private) insurance face a different problem. Their plan may cover Evenity but impose high copays or coinsurance. Amgen's Evenity copay assistance program addresses this gap directly.

The copay card reduces out-of-pocket costs to as little as $0 per dose, with a maximum annual benefit of up to $15,000. Given that 12 doses at even a 20% coinsurance rate on a $1,825 list price would total $4,380, the $15,000 cap covers most commercially insured patients for the full treatment course.

Who qualifies: U.S. residents aged 18 or older with commercial insurance that covers Evenity. Government-funded insurance (Medicare, Medicaid, Tricare, VA) beneficiaries are specifically excluded from copay card programs under federal anti-kickback statutes.

Enrollment happens through the prescriber's office or by calling the number on the Amgen support website. The card activates at the pharmacy or buy-and-bill provider, and discounts apply automatically at the point of sale. Patients should confirm that their pharmacy or provider accepts copay cards before the first injection to avoid billing surprises.

Medicare and Medicaid Coverage Pathways

For patients on government insurance, the financial picture is more complex. The copay card is off the table. But coverage itself is often available.

Medicare Part B may cover Evenity when it is administered in a physician's office as a "buy and bill" medication. Under Part B, the patient pays 20% coinsurance after meeting the annual deductible. For a $1,825 injection, that coinsurance comes to roughly $365 per dose. A Medigap (supplemental) policy can cover some or all of that 20%.

Medicare Part D may cover Evenity if it is dispensed through a specialty pharmacy rather than administered in-office. Under Part D, patients may face high costs during the coverage gap (the "donut hole"), though the Inflation Reduction Act of 2022 capped annual out-of-pocket Part D spending at $2,000 starting in 2025 [3]. This cap significantly reduces the financial exposure for Medicare beneficiaries using high-cost specialty drugs.

Medicaid coverage varies by state. Most state Medicaid programs have formulary committees that evaluate specialty biologics individually. Prior authorization is nearly universal. Patients whose Medicaid plan denies coverage should request a formal appeal and ask the prescriber to submit a letter of medical necessity citing the AACE 2020 osteoporosis guidelines, which position romosozumab as a first-line option for patients at very high fracture risk [4].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and a principal investigator on the FRAME trial, has stated: "Romosozumab fills a genuine unmet need for patients who have already fractured or whose bone density is critically low. The clinical evidence supports its use as initial therapy in the highest-risk patients, not as a last resort."

Independent Foundations and Nonprofit Grants

Several independent charitable foundations offer copay assistance or direct grants for osteoporosis medications, including romosozumab.

HealthWell Foundation operates an Osteoporosis Fund that helps cover copays, premiums, and related costs. Eligibility is income-based (typically up to 500% FPL) and the fund opens and closes periodically depending on available donations. Patients should apply early and check the HealthWell Foundation website for fund status.

Patient Access Network (PAN) Foundation runs a similar osteoporosis assistance program. PAN grants can cover insurance premiums, copays, and travel costs related to treatment. Income limits generally fall at or below 400% FPL.

NeedyMeds maintains a searchable database of patient assistance programs, discount cards, and free clinic resources. While NeedyMeds does not provide grants directly, it aggregates information from hundreds of programs and can surface options specific to romosozumab that individual patients might miss.

The Bone Health and Osteoporosis Foundation (BHOF) offers educational resources and can connect patients to local support. While BHOF does not provide direct financial aid, its helpline staff can guide patients through the application process for other programs.

A practical approach: apply to multiple programs simultaneously. Foundation funds deplete quickly, and having a backup reduces the risk of treatment delay.

Insurance Prior Authorization: How to Get Approved

Most private insurers and Medicare plans require prior authorization (PA) before covering Evenity. The PA process evaluates whether the patient meets specific clinical criteria. Denials are common on the first attempt, but approvals increase substantially on appeal.

Typical criteria insurers require include a confirmed diagnosis of osteoporosis (T-score of -2.5 or lower at the spine or hip), documented high fracture risk (prior fragility fracture, FRAX score above the treatment threshold, or multiple clinical risk factors), and evidence that the patient has tried or is intolerant to at least one oral bisphosphonate [5]. Some plans waive the bisphosphonate step-therapy requirement for patients with very high fracture risk, consistent with the AACE guidelines.

If your PA is denied, the prescriber should file a formal appeal. The appeal letter should reference the ARCH trial (N=4,093), which demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone at 24 months [6]. It should also note the Endocrine Society clinical practice guideline, which recommends anabolic therapy as initial treatment for patients at very high fracture risk rather than reserving it as second-line [7].

Appeals succeed more often than most patients expect. A 2022 study published in JAMA Internal Medicine found that 45% of specialty drug denials were overturned on first appeal, and 61% were overturned when a peer-to-peer review was requested [8].

Buy-and-Bill vs. Specialty Pharmacy: Which Route Saves More?

How Evenity is dispensed affects which insurance benefit covers it and what the patient ultimately pays.

Buy-and-bill means the physician's office purchases the drug, administers it, and bills the insurer. This routes through the medical benefit (Part B for Medicare, medical benefit for commercial plans). The advantage: medical benefit copays and deductibles are often lower than pharmacy benefit tiers. The disadvantage: some practices will not stock a $1,825-per-dose biologic due to cash flow constraints.

Specialty pharmacy dispensing means the drug ships to the patient or provider from a specialty pharmacy. This routes through the pharmacy benefit (Part D for Medicare, pharmacy tier for commercial plans). Specialty tiers commonly impose 25% to 33% coinsurance, though annual out-of-pocket maximums cap total exposure.

Ask your insurance company which route they prefer. Then ask your prescriber which route they support. The intersection of those two answers determines your path. In some cases, switching from pharmacy to medical benefit (or vice versa) can save thousands of dollars over the 12-month course.

Comparing Romosozumab Costs to Alternative Osteoporosis Therapies

Cost context helps frame the assistance decision. Generic alendronate costs $10 to $30 per month. Denosumab (Prolia) runs approximately $1,800 per injection given every 6 months, with its own copay assistance program from Amgen. Teriparatide (Forteo) costs roughly $3,700 per month for daily injections over 24 months, though generic teriparatide has lowered that figure in recent years. Abaloparatide (Tymlos) costs approximately $3,200 per month [9].

Romosozumab's total course cost ($21,900 over 12 months) is actually comparable to or lower than the total cost of teriparatide ($44,400+ over 24 months at branded pricing) when viewed as a complete treatment cycle. The 12-month fixed duration is a financial advantage: the cost is bounded, unlike bisphosphonates that may continue for 5 or more years.

The FRAME trial (N=7,180) showed that romosozumab increased lumbar spine BMD by 13.3% at 12 months versus 0.0% with placebo, with a 73% relative reduction in new vertebral fractures [10]. That efficacy, compressed into a 12-month window, means the cost-per-fracture-prevented may favor romosozumab over longer, cheaper regimens in very high-risk patients. A cost-effectiveness analysis published in the Journal of Bone and Mineral Research estimated romosozumab-to-alendronate sequencing at $52,000 to $78,000 per quality-adjusted life year (QALY), which falls below the commonly cited $100,000-per-QALY willingness-to-pay threshold [11].

Step-by-Step: Building Your Assistance Plan

The process works best when patients and prescribers coordinate early. Do not wait until the first injection is scheduled.

Step 1. Confirm insurance status. Know whether you have commercial insurance, Medicare (Part B, Part D, or both), Medicaid, or no coverage.

Step 2. Call your insurer and ask whether Evenity is covered, which benefit it falls under (medical vs. pharmacy), and what your estimated copay or coinsurance will be.

Step 3. If uninsured or underinsured, apply to Amgen Assist immediately. Have income documentation ready.

Step 4. If commercially insured, enroll in the Evenity copay card through your prescriber's office or the Amgen support line.

Step 5. Apply to at least two independent foundations (HealthWell, PAN) regardless of insurance status. These grants stack with other assistance in many cases.

Step 6. If prior authorization is required, ensure your prescriber submits clinical documentation that specifically references very high fracture risk, prior fractures, and guideline recommendations for anabolic-first therapy.

Step 7. If denied, appeal. Request a peer-to-peer review between your prescriber and the insurer's medical director. Cite the ARCH and FRAME trial data directly in the appeal letter.

Programs change their eligibility criteria and funding levels frequently. Verify all details directly with Amgen's support resources and each foundation before relying on any specific benefit amount or income threshold.